跳至主要内容
临床试验/NCT04061213
NCT04061213进行中(未招募)不适用

ATTR Amyloidosis in Elderly Patients With Aortic Stenosis

Insel Gruppe AG, University Hospital Bern1 个研究点 分布在 1 个国家目标入组 489 人开始时间: 2019年8月26日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
489
试验地点
1
主要终点
Proportion of patients with grade 2 or 3 cardiac uptake in scintigraphy and without pathological light chains in immunological assays

研究概览

简要总结

Severe aortic stenosis is defined with a mean transvalvular pressure gradient (MTPG) > 40mmHg and a calculated aortic valve area of < 1cm2. However, a considerable proportion of patients do have a MTPG < 40mmHg due to a reduced stroke volume (stroke volume indexed to body surface area ≤ 35ml/m2) despite a normal left ventricular ejection fraction (LVEF > 50%). This entity is termed paradoxical low flow low gradient aortic stenosis (PLFLG AS) and is associated with a worse prognosis.

ATTR amyloidosis is a disease of the elderly and might coexist in patients with severe aortic stenosis. Case reports and small observational studies suggest that senile ATTR amyloidosis could be frequent but underdiagnosed in patients with aortic stenosis. There is significant overlap between PLFLG AS and cardiac amyloidosis with regard to symptoms, increasing prevalence with age, concentric hypertrophy, impaired diastolic filling of the left ventricle (LV), as well as longitudinal LV dysfunction despite preserved ejection fraction - all features, which lead to a reduction in stroke volume, the underlying mechanism of the low flow condition as observed in PLFLG AS patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Symptomatic, severe aortic stenosis

排除标准

  • More than mild valvular disease of any other valve
  • Other severe disease with a life expectancy < 1 year
  • Participating in trial interfering with routine clinical practice or use of a non-CE marked device

结局指标

主要结局

Proportion of patients with grade 2 or 3 cardiac uptake in scintigraphy and without pathological light chains in immunological assays

时间窗: In-Hospital [7 days]

Evaluation of incidence rate

次要结局

  • All-cause and cardiovascular mortality(30 days, 12months)
  • CPET - maximal exercise capacity(In-Hospital [7 days])

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验